Lab
Cellnetix Labs, LLC
Cellnetix Labs, LLC was paid $8.43M by Medicaid between Jan 2018 and Dec 2024, across 40 billing codes. Its largest line is 88175, Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer — 23% of everything it billed.
33Billing provider infoCELLNETIX LABS, LLC
TUKWILA, WA 98168
TUKWILA, WA 98168
33aNPI1407060411assigned 05/09/2007
33bProvider typeClinical Medical Laboratory
28Total paid$8.43M
24GClaims321,575
24DCodes billed40
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Washington
Rank by total paid#12 of 76
Median peer was paid$90K
This provider vs. median93×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 70,246 | $2.11M | |
| 2019 | 52,183 | $1.45M | |
| 2020 | 36,905 | $869K | |
| 2021 | 44,524 | $1.08M | |
| 2022 | 43,457 | $1.08M | |
| 2023 | 42,081 | $1.04M | |
| 2024incomplete | 32,179 | $809K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 23% | 83,129 | 80,205 | $1.92M |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 21% | 64,612 | 60,535 | $1.74M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 13% | 55,044 | 40,744 | $1.06M |
| 88307 | 8.0% | 6,701 | 5,406 | $671K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 5.2% | 16,849 | 15,770 | $438K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 5.2% | 16,861 | 15,784 | $437K |
| 88342 | 4.2% | 10,895 | 8,933 | $351K | |
| 88341 | 3.8% | 6,657 | 4,104 | $322K | |
| 88185 | 2.2% | 1,001 | 651 | $190K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 2.1% | 7,127 | 6,759 | $173K |
| 87625 | 1.9% | 8,229 | 7,118 | $157K | |
| 87481 | 1.8% | 5,045 | 3,004 | $153K |
28 more codes
| 88304 | 1.5% | 8,929 | $127K | |
| 88312 | 1.2% | 2,765 | $104K | |
| 88173 | 1.1% | 2,502 | $95K | |
| 88360 | <1% | 2,263 | $69K | |
| 88142 | <1% | 4,053 | $65K | |
| 88112 | <1% | 4,010 | $61K | |
| 88313 | <1% | 986 | $36K | |
| 88309 | <1% | 285 | $36K | |
| 88374 | <1% | 363 | $35K | |
| 87511 | <1% | 1,379 | $34K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,306 | $26K |
| 88361 | <1% | 606 | $24K | |
| 88184 | <1% | 948 | $24K | |
| 81513 | <1% | 1,843 | $16K | |
| 88302 | <1% | 1,024 | $12K | |
| 88331 | <1% | 466 | $9K | |
| 87480 | <1% | 306 | $6K | |
| 87660 | <1% | 308 | $6K | |
| 87510 | <1% | 294 | $5K | |
| 88311 | <1% | 1,030 | $4K | |
| 88333 | <1% | 409 | $4K | |
| 88381 | <1% | 140 | $4K | |
| 88237 | <1% | 59 | $3K | |
| 88172 | <1% | 209 | $2K | |
| 88344 | <1% | 12 | $1K | |
| 88300 | <1% | 137 | $710.04 | |
| 88108 | <1% | 14 | $191.35 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 2,779 | $32.05 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKIEHN, DAVID (CFO)